- Home
- DGICA vs GHRS Comparison
DGICA vs GHRS Comparison
Compare DGICA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- GHRS
- Stock Information
- Founded
- DGICA 1986
- GHRS 2018
- Country
- DGICA United States
- GHRS Ireland
- Employees
- DGICA N/A
- GHRS N/A
- Industry
- DGICA Property-Casualty Insurers
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- GHRS Health Care
- Exchange
- DGICA Nasdaq
- GHRS Nasdaq
- Market Cap
- DGICA 705.0M
- GHRS 839.9M
- IPO Year
- DGICA N/A
- GHRS 2021
- Fundamental
- Price
- DGICA $20.00
- GHRS $14.06
- Analyst Decision
- DGICA Hold
- GHRS Strong Buy
- Analyst Count
- DGICA 1
- GHRS 10
- Target Price
- DGICA $18.00
- GHRS $29.90
- AVG Volume (30 Days)
- DGICA 110.3K
- GHRS 387.9K
- Earning Date
- DGICA 10-30-2025
- GHRS 11-06-2025
- Dividend Yield
- DGICA 3.65%
- GHRS N/A
- EPS Growth
- DGICA 219.91
- GHRS N/A
- EPS
- DGICA 2.38
- GHRS N/A
- Revenue
- DGICA $987,826,105.00
- GHRS N/A
- Revenue This Year
- DGICA $2.26
- GHRS N/A
- Revenue Next Year
- DGICA $3.46
- GHRS N/A
- P/E Ratio
- DGICA $8.39
- GHRS N/A
- Revenue Growth
- DGICA 0.89
- GHRS N/A
- 52 Week Low
- DGICA $14.17
- GHRS $6.72
- 52 Week High
- DGICA $21.12
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- DGICA 64.30
- GHRS 52.55
- Support Level
- DGICA $19.42
- GHRS $13.35
- Resistance Level
- DGICA $20.00
- GHRS $15.31
- Average True Range (ATR)
- DGICA 0.48
- GHRS 1.04
- MACD
- DGICA 0.12
- GHRS 0.05
- Stochastic Oscillator
- DGICA 97.53
- GHRS 56.02
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.